CRISPR Therapeutics AG Common Shares is a leading biotechnology firm specializing in gene-editing technology. With a focus on developing transformative therapies for severe genetic diseases, they are at the forefront of cutting-edge scientific research. Their innovative approach holds great potential to revolutionize the field of medicine.